The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on INSM stock, giving a Buy rating on November 5. Graig ...

Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

They compared patients prescribed semaglutide—a glucagon-like peptide-1 (GLP-1) receptor agonist—to those prescribed one of seven other anti-diabetic drugs, including metformin, dipeptidyl ...

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed (INSM – Research Report), with a price ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Semaglutide, the active ingredient in Ozempic and Wegovy, may also help lower the risk of developing Alzheimer’s disease in people living with type 2 diabetes.